Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Zika Virus Infection | 10 | 2019 | 32 | 2.550 |
Why?
|
| Antibodies, Viral | 10 | 2019 | 293 | 2.250 |
Why?
|
| Antibodies, Neutralizing | 7 | 2018 | 179 | 2.200 |
Why?
|
| Zika Virus | 7 | 2019 | 32 | 1.720 |
Why?
|
| Dengue Virus | 5 | 2017 | 95 | 1.380 |
Why?
|
| Antibodies, Monoclonal | 4 | 2017 | 837 | 1.340 |
Why?
|
| Dengue Vaccines | 3 | 2017 | 7 | 0.750 |
Why?
|
| Neck Injuries | 1 | 2019 | 19 | 0.650 |
Why?
|
| Facial Injuries | 1 | 2019 | 13 | 0.650 |
Why?
|
| Deglutition Disorders | 1 | 2019 | 41 | 0.640 |
Why?
|
| Burns | 1 | 2019 | 41 | 0.630 |
Why?
|
| SAIDS Vaccines | 4 | 2019 | 18 | 0.610 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 4 | 2019 | 51 | 0.590 |
Why?
|
| Plasma Cells | 1 | 2017 | 49 | 0.550 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 43 | 0.550 |
Why?
|
| Immunodominant Epitopes | 1 | 2017 | 56 | 0.540 |
Why?
|
| Macaca mulatta | 8 | 2019 | 229 | 0.480 |
Why?
|
| Simian Immunodeficiency Virus | 4 | 2019 | 68 | 0.470 |
Why?
|
| Pregnancy Complications | 1 | 2018 | 367 | 0.430 |
Why?
|
| Dependovirus | 1 | 2017 | 653 | 0.360 |
Why?
|
| Gene Products, vif | 2 | 2019 | 9 | 0.310 |
Why?
|
| Gene Products, nef | 2 | 2019 | 13 | 0.310 |
Why?
|
| Animals | 15 | 2019 | 19705 | 0.250 |
Why?
|
| Immunoglobulin G | 2 | 2017 | 446 | 0.240 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2019 | 649 | 0.240 |
Why?
|
| Viral Load | 3 | 2019 | 220 | 0.210 |
Why?
|
| T-Lymphocytes | 2 | 2017 | 987 | 0.200 |
Why?
|
| Female | 9 | 2019 | 30925 | 0.170 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2019 | 135 | 0.170 |
Why?
|
| Rectum | 2 | 2019 | 86 | 0.170 |
Why?
|
| Male | 7 | 2019 | 27952 | 0.170 |
Why?
|
| Antibody-Dependent Enhancement | 1 | 2019 | 4 | 0.160 |
Why?
|
| Immune Sera | 1 | 2019 | 34 | 0.160 |
Why?
|
| Epidemics | 1 | 2019 | 22 | 0.160 |
Why?
|
| Humans | 12 | 2019 | 59737 | 0.150 |
Why?
|
| Gene Products, env | 1 | 2018 | 17 | 0.150 |
Why?
|
| Fetal Death | 1 | 2018 | 12 | 0.150 |
Why?
|
| Simian T-lymphotropic virus 1 | 1 | 2017 | 1 | 0.140 |
Why?
|
| Gene Products, tax | 1 | 2017 | 1 | 0.140 |
Why?
|
| HTLV-I Infections | 1 | 2017 | 3 | 0.140 |
Why?
|
| Macaca | 1 | 2017 | 30 | 0.140 |
Why?
|
| Immunoglobulin M | 1 | 2017 | 114 | 0.140 |
Why?
|
| Immunity, Humoral | 1 | 2017 | 37 | 0.140 |
Why?
|
| Herpesviridae | 1 | 2017 | 14 | 0.140 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2017 | 35 | 0.140 |
Why?
|
| Dengue | 1 | 2017 | 92 | 0.130 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2017 | 111 | 0.130 |
Why?
|
| RNA, Viral | 4 | 2019 | 259 | 0.130 |
Why?
|
| Genomics | 1 | 2019 | 322 | 0.130 |
Why?
|
| Adult | 5 | 2019 | 15771 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 446 | 0.130 |
Why?
|
| Flow Cytometry | 1 | 2017 | 645 | 0.120 |
Why?
|
| HEK293 Cells | 1 | 2017 | 588 | 0.120 |
Why?
|
| Drug Carriers | 1 | 2017 | 175 | 0.120 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1489 | 0.110 |
Why?
|
| Pregnancy | 2 | 2018 | 2226 | 0.110 |
Why?
|
| Viremia | 3 | 2019 | 44 | 0.110 |
Why?
|
| Brucella melitensis | 1 | 2013 | 1 | 0.110 |
Why?
|
| Amino Acid Sequence | 1 | 2017 | 1556 | 0.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 621 | 0.110 |
Why?
|
| Middle Aged | 3 | 2019 | 16449 | 0.100 |
Why?
|
| Virulence Factors | 1 | 2013 | 80 | 0.100 |
Why?
|
| Unfolded Protein Response | 1 | 2013 | 55 | 0.100 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 2390 | 0.100 |
Why?
|
| Young Adult | 2 | 2019 | 4290 | 0.100 |
Why?
|
| Prospective Studies | 1 | 2019 | 3090 | 0.100 |
Why?
|
| HIV-1 | 1 | 2017 | 692 | 0.100 |
Why?
|
| Adolescent | 2 | 2019 | 5866 | 0.090 |
Why?
|
| HIV Infections | 1 | 2017 | 915 | 0.090 |
Why?
|
| Brain | 1 | 2018 | 1495 | 0.080 |
Why?
|
| Aedes | 2 | 2019 | 12 | 0.080 |
Why?
|
| Vaccines, Synthetic | 2 | 2019 | 68 | 0.070 |
Why?
|
| Bacterial Proteins | 1 | 2013 | 738 | 0.070 |
Why?
|
| Macrophages | 1 | 2013 | 1015 | 0.070 |
Why?
|
| Cross Reactions | 2 | 2017 | 127 | 0.070 |
Why?
|
| Florida | 2 | 2017 | 42 | 0.070 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2019 | 177 | 0.070 |
Why?
|
| Phylogeny | 2 | 2019 | 337 | 0.070 |
Why?
|
| Disease Outbreaks | 2 | 2017 | 104 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 2060 | 0.070 |
Why?
|
| Genome, Viral | 2 | 2017 | 122 | 0.070 |
Why?
|
| Immunity, Cellular | 2 | 2017 | 171 | 0.070 |
Why?
|
| Virus Replication | 2 | 2018 | 305 | 0.060 |
Why?
|
| Incidence | 2 | 2019 | 1245 | 0.060 |
Why?
|
| United States | 1 | 2017 | 7448 | 0.060 |
Why?
|
| Cuba | 1 | 2019 | 1 | 0.040 |
Why?
|
| Immunization Schedule | 1 | 2019 | 17 | 0.040 |
Why?
|
| West Indies | 1 | 2019 | 6 | 0.040 |
Why?
|
| Mosquito Control | 1 | 2019 | 6 | 0.040 |
Why?
|
| CTLA-4 Antigen | 1 | 2019 | 70 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 2019 | 40 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2019 | 100 | 0.040 |
Why?
|
| Travel | 1 | 2019 | 37 | 0.040 |
Why?
|
| Viral Vaccines | 1 | 2019 | 47 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2019 | 160 | 0.040 |
Why?
|
| Vaccines, Attenuated | 1 | 2017 | 33 | 0.040 |
Why?
|
| Papio anubis | 1 | 2017 | 2 | 0.040 |
Why?
|
| Animals, Newborn | 1 | 2018 | 230 | 0.040 |
Why?
|
| Exanthema | 1 | 2017 | 26 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2019 | 257 | 0.040 |
Why?
|
| Americas | 1 | 2017 | 5 | 0.040 |
Why?
|
| Asia | 1 | 2017 | 18 | 0.040 |
Why?
|
| Africa | 1 | 2017 | 21 | 0.030 |
Why?
|
| Mosquito Vectors | 1 | 2017 | 11 | 0.030 |
Why?
|
| Molecular Epidemiology | 1 | 2017 | 25 | 0.030 |
Why?
|
| Caribbean Region | 1 | 2017 | 21 | 0.030 |
Why?
|
| Nervous System Malformations | 1 | 2017 | 12 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 43 | 0.030 |
Why?
|
| Viral Envelope Proteins | 1 | 2017 | 100 | 0.030 |
Why?
|
| Disease Transmission, Infectious | 1 | 2017 | 21 | 0.030 |
Why?
|
| Communicable Disease Control | 1 | 2017 | 37 | 0.030 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2017 | 71 | 0.030 |
Why?
|
| Alleles | 1 | 2018 | 412 | 0.030 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2017 | 53 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 235 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2017 | 223 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2017 | 89 | 0.030 |
Why?
|
| Vaccination | 1 | 2019 | 335 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 499 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 264 | 0.030 |
Why?
|
| Viral Proteins | 1 | 2017 | 256 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2017 | 551 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 588 | 0.030 |
Why?
|
| Brucellosis | 1 | 2013 | 3 | 0.030 |
Why?
|
| Microbial Viability | 1 | 2013 | 57 | 0.030 |
Why?
|
| Mice | 2 | 2019 | 10316 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2017 | 1802 | 0.020 |
Why?
|
| Dogs | 1 | 2013 | 316 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 870 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 2387 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2095 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 2068 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2013 | 2000 | 0.020 |
Why?
|
| Child | 1 | 2017 | 4215 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2017 | 5334 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 3240 | 0.020 |
Why?
|
| Aged | 1 | 2017 | 13510 | 0.010 |
Why?
|